glp-1/gip GLP-1 & GIP Agonists | Obesity and Diabetes Management | Harrison's updates (22nd Ed.) Science Behind GLP 1 GIP

Learn about the Ozempic blindness lawsuit, including NAION and other vision problems, and read about the study linking semaglutide use to severe eye problems.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, have emerged as transformative agents for type 2 diabetes and obesity through their potent effects on weight reduction, insulin sensitivity, and cardiovascular outcomes

Even more concerning

Dr Reddys launches oral semaglutide biosimilar tablets, offering broader access to diabetes and weight-loss therapies in India.

While drug manufacturers sometimes offer discount programs, consumers are often left paying hundreds of dollars out of pocket for their prescriptions